Phaseline

Targets › NGLY1

NGLY1 (Peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Metabolic and endocrine; next expected readout Mar 2027.

Protein N-glycosidase that mediates deglycosylation of N-linked glycoproteins by cleaving the beta-aspartyl-glucosamine (GlcNAc) of the glycan and the amide side chain of asparagine (Asn), converting Asn to aspartate (Asp). Prefers proteins containing high-mannose over those bearing complex type oligosaccharides. (UniProt, Q96IV0)

Open in Phaseline: the race on NGLY1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Grace ScienceGS-100
Gene replacement therapy for NGLY1 deficiency delivered via intracerebroventricular admini
NGLY1Phase 3NGLY1 DeficiencyMar 2027

Conditions

NGLY1 Deficiency (1)

Modalities

other (1)

Companies

Grace Science (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.